Joining Forces: Bmi1 Inhibition and Cisplatin Curb Squamous Carcinogenesis

Head and neck squamous cell carcinomas (HNSCCs) are refractory to therapeutic interventions. Chen et al. (2017) show that mouse and human HNSCCs and their metastases depend on Bmi1-expressing cancer stem cells and AP1 signaling and that simultaneously inhibiting Bmi1 or AP1, combined with Cisplatin,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell stem cell 2017-05, Vol.20 (5), p.575-577
Hauptverfasser:	Brown, Jessie A., Schober, Markus
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - therapeutic use Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - metabolism Cisplatin - therapeutic use Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - metabolism Humans Mice Models, Biological Polycomb Repressive Complex 1 - antagonists & inhibitors Polycomb Repressive Complex 1 - metabolism Signal Transduction - drug effects Squamous Cell Carcinoma of Head and Neck Tamoxifen - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Head and neck squamous cell carcinomas (HNSCCs) are refractory to therapeutic interventions. Chen et al. (2017) show that mouse and human HNSCCs and their metastases depend on Bmi1-expressing cancer stem cells and AP1 signaling and that simultaneously inhibiting Bmi1 or AP1, combined with Cisplatin, reduces tumor growth effectively in preclinical models. Head and neck squamous cell carcinomas (HNSCCs) are refractory to therapeutic interventions. Chen et al. (2017) show that mouse and human HNSCCs and their metastases depend on Bmi1-expressing cancer stem cells and AP1 signaling and that simultaneously inhibiting Bmi1 or AP1, combined with Cisplatin, reduces tumor growth effectively in preclinical models.
ISSN:	1934-5909 1875-9777
DOI:	10.1016/j.stem.2017.04.008